<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01952782</url>
  </required_header>
  <id_info>
    <org_study_id>2013P001543</org_study_id>
    <nct_id>NCT01952782</nct_id>
  </id_info>
  <brief_title>Neuropeptides in Human Reproduction</brief_title>
  <official_title>Neuropeptides in Human Reproduction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators are seeking healthy volunteers and volunteers with reproductive disorders&#xD;
      for the study of the role of dynorphin in the reproductive system. Dynorphin is a naturally&#xD;
      occurring opioid hormone that is blocked by naloxone.&#xD;
&#xD;
      We hypothesize that naloxone, by blocking dynorphin, will stimulate production of GnRH and&#xD;
      kisspeptin, 2 other naturally occurring reproductive hormones.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">August 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Average difference in luteinizing hormone (LH) concentration before and after kisspeptin</measure>
    <time_frame>Within 30 minutes of administration</time_frame>
    <description>Compares response to kisspeptin on and off naloxone infusion</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">128</enrollment>
  <condition>Hypogonadotropic Hypogonadism</condition>
  <arm_group>
    <arm_group_label>Naloxone, Kisspeptin, GnRH</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The study will involve 3 visits:&#xD;
Outpatient screening visit&#xD;
Inpatient admission where subjects receive an intravenous infusion of naloxone, intravenous doses of kisspeptin 112-121, and intravenous doses of Gonadotropin Releasing Hormone (GnRH)&#xD;
Outpatient follow-up visit</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Kisspeptin 112-121</intervention_name>
    <description>Subjects will receive up to 10 intravenous doses of kisspeptin 112-121</description>
    <arm_group_label>Naloxone, Kisspeptin, GnRH</arm_group_label>
    <other_name>Metastin 45-54</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naloxone</intervention_name>
    <description>Subjects will receive one intravenous dose of naloxone followed by an intravenous infusion of naloxone.</description>
    <arm_group_label>Naloxone, Kisspeptin, GnRH</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gonadotropin Releasing Hormone (GnRH)</intervention_name>
    <description>Subjects will receive up to 10 doses of intravenous Gonadotropin Releasing Hormone (GnRH)</description>
    <arm_group_label>Naloxone, Kisspeptin, GnRH</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Ages 21-40 (healthy men and regularly cycling women) OR ages 18-75 (men and women with&#xD;
             hypogonadotropic hypogonadism (HH))&#xD;
&#xD;
          -  Normal blood pressure (systolic BP &lt;140 mm Hg, diastolic BP &lt;90 mm Hg)&#xD;
&#xD;
          -  White blood cell, platelets, prolactin, and thyroid stimulating hormone (TSH)within&#xD;
             90%-110% of laboratory reference range&#xD;
&#xD;
          -  Negative urine drug screen panel&#xD;
&#xD;
          -  Hemoglobin:&#xD;
&#xD;
               1. For healthy men and healthy regularly cycling women: normal&#xD;
&#xD;
               2. For men and women with HH: No less than 0.5 gm/dL below the lower limit of the&#xD;
                  reference range for normal women&#xD;
&#xD;
          -  Blood urea nitrogen (BUN), creatinine, liver function tests not elevated&#xD;
&#xD;
          -  For healthy subjects: Normal reproductive function and history&#xD;
&#xD;
          -  For healthy subjects: Body Mass Index (BMI) 18.5-30kg/m2&#xD;
&#xD;
          -  For subjects with HH: All medical conditions stable and well controlled&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of medication reaction requiring emergency medical attention&#xD;
&#xD;
          -  Illicit drug use&#xD;
&#xD;
          -  Consumption of more than 10 alcoholic drinks per week&#xD;
&#xD;
          -  Difficulty with blood draws&#xD;
&#xD;
          -  Currently seeking fertility, breastfeeding, or pregnant&#xD;
&#xD;
          -  For healthy subjects: history of chronic disease and prescription medication use (with&#xD;
             the exception of seasonal allergy medication)&#xD;
&#xD;
          -  For subjects with HH: prescription medications known to affect reproductive endocrine&#xD;
             function except for those used to treat the subject's reproductive condition&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephanie B Seminara, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Study Coordinator</last_name>
    <phone>617-726-8484</phone>
    <email>MGHKisspeptinResearch@partners.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Stephanie B Seminara, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yee-Ming Chan, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Margaret Lippincott, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>September 24, 2013</study_first_submitted>
  <study_first_submitted_qc>September 24, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 30, 2013</study_first_posted>
  <last_update_submitted>July 1, 2021</last_update_submitted>
  <last_update_submitted_qc>July 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Stephanie B. Seminara, MD</investigator_full_name>
    <investigator_title>Chief, Reproductive Endocrine Unit; Professor of Medicine, Harvard Medical School; Director, Harvard Reproductive Endocrine Sciences Center</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypogonadism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Naloxone</mesh_term>
    <mesh_term>Hormones</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

